Search research articles
Contact Us
Filters
Showing results (311-320 of 404) with videos related to
Page
of 41
Sort By:
Cancers
|
May 14, 2022
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
Umberto Basso, Federico Paolieri, Mimma Rizzo, et al.
Oncotarget
|
August 9, 2015
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
Rossana Berardi, Alessandro Brunelli, Silvia Pagliaretta, et al.
European Urology Open Science
|
October 27, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)
Marco Stellato, Pierangela Sepe, Enrico Bronte, et al.
Targeted Oncology
|
August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
Matteo Santoni, Francesco Massari, Enrique Grande, et al.
Expert Opinion on Pharmacotherapy
|
February 4, 2026
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group
Concetta Calabrò, Francesco Ciccimarra, Alessandro Rizzo, et al.
Plos One
|
April 12, 2016
Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis
Paolo Grassi, Ludovic Doucet, Palma Giglione, et al.
Targeted Oncology
|
January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
Matteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Clinical Genitourinary Cancer
|
December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study
Fernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Therapeutic Advances in Urology
|
April 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients
Sebastiano Buti, Alessandro Olivari, Cristina Masini, et al.
Journal of Clinical Medicine
|
June 26, 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
Vincenza Conteduca, Orazio Caffo, Emanuela Scarpi, et al.
Page
of 41
Search research articles
Search
Showing results (311-320 of 404) with videos related to
Sort By:
Page
of 41
Cancers
|
May 14, 2022
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
Umberto Basso, Federico Paolieri, Mimma Rizzo, et al.
Oncotarget
|
August 9, 2015
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
Rossana Berardi, Alessandro Brunelli, Silvia Pagliaretta, et al.
European Urology Open Science
|
October 27, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)
Marco Stellato, Pierangela Sepe, Enrico Bronte, et al.
Targeted Oncology
|
August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
Matteo Santoni, Francesco Massari, Enrique Grande, et al.
Expert Opinion on Pharmacotherapy
|
February 4, 2026
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group
Concetta Calabrò, Francesco Ciccimarra, Alessandro Rizzo, et al.
Plos One
|
April 12, 2016
Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis
Paolo Grassi, Ludovic Doucet, Palma Giglione, et al.
Targeted Oncology
|
January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
Matteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Clinical Genitourinary Cancer
|
December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study
Fernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Therapeutic Advances in Urology
|
April 19, 2024
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients
Sebastiano Buti, Alessandro Olivari, Cristina Masini, et al.
Journal of Clinical Medicine
|
June 26, 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
Vincenza Conteduca, Orazio Caffo, Emanuela Scarpi, et al.
Page
of 41